Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
27 févr. 2020 16h30 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
10 déc. 2018 09h00 HE
|
Denali Therapeutics Inc.
Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:...